phrykt

Cabaletta Bio, Inc. (CABA): who owns it and who trades it

As of Nov 16, 2026, CABA insiders reported 8 purchases worth $296K in the last 12 months. The largest buyer was Steven Nichtberger (CEO), with $101K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cabaletta Bio

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CABA

140 funds and institutions reported CABA shares worth $494M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jennison Associates LLC with 18.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Jennison Associates LLC18.0%
T. Rowe Price Investment Management, Inc.17.0%
Bain Capital Life Sciences Investors, LLC15.5%
BlackRock, Inc.9.7%
Adage Capital Partners Gp, L.l.c.8.2%
State Street Corp7.0%
Vanguard Capital Management LLC6.5%
Cormorant Asset Management, LP4.5%
T. Rowe Price Associates4.0%
Woodline Partners LP3.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jennison Associates LLC20.03M18.00%$62.3M+123%
T. Rowe Price Investment Management, Inc.18.87M16.95%$58.7M+70%
Bain Capital Life Sciences Investors, LLC17.24M15.49%$53.6M+78%
BlackRock, Inc.10.75M9.66%$33.4M+353%
Adage Capital Partners Gp, L.l.c.9.17M8.24%$28.5M+4%
State Street Corp7.84M7.04%$24.4M+1568%
Vanguard Capital Management LLC7.23M6.49%$22.5M+79%
Cormorant Asset Management, LP5.00M4.49%$15.6M-9%
T. Rowe Price Associates4.42M3.97%$13.7M+899%
Woodline Partners LP4.20M3.77%$13.1M+236%
Norges Bank4.11M3.69%$12.8M–
Opaleye Management Inc.3.86M3.47%$12M+180%
Citadel Advisors LLC3.52M3.16%$11M–
Geode Capital Management, LLC3.46M3.11%$10.8M+205%
Franklin Resources Inc2.41M2.17%$7.5M–
Goldman Sachs Group Inc2.21M1.99%$6.9M+182%
Millennium Management LLC2.07M1.86%$6.4M-65%
Cantor Fitzgerald, L. P.1.60M1.44%$5M+109%
Marshall Wace, LLP1.57M1.41%$4.9M-28%
Renaissance Technologies LLC1.54M1.38%$4.8M-25%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CABA insiders reported $296K of open-market purchases and $0 of sales.

Purchases, 12 months
$296K
8 trades, 8 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jan 21, 2026
Filed Jan 21, 2026

Purchases and sales by month

$296K$296KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jan 21, 2026David J. ChangChief Medical OfficerPurchase8,800$2.26$19.9KForm 4
Jan 21, 2026Gwendolyn BinderPresidentPurchase11,312$2.19$24.8KForm 4
Jan 21, 2026Shawn TomaselloDirectorPurchase22,725$2.21$50.2KForm 4
Jan 21, 2026Steve GavelChief Commercial OfficerPurchase22,170$2.27$50.3KForm 4
Jan 21, 2026Catherine BollardDirectorPurchase4,405$2.27$10KForm 4
Jan 21, 2026Steven NichtbergerCEOPurchase45,000$2.24$101KForm 4
Jan 21, 2026Mark SimonDirectorPurchase11,061$2.28$25.2KForm 4
Jan 21, 2026Michael GerardGeneral CounselPurchase6,600$2.27$15KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Steven NichtbergerPresident & CEO, Director$101K–Jan 21, 2026
Steve GavelChief Commercial Officer$50.3K–Jan 21, 2026
Shawn TomaselloDirector$50.2K–Jan 21, 2026
Mark SimonDirector$25.2K–Jan 21, 2026
Gwendolyn BinderPresident, Science & Tech.$24.8K–Jan 21, 2026
David J. ChangChief Medical Officer$19.9K–Jan 21, 2026
Michael GerardGeneral Counsel$15K–Jan 21, 2026
Catherine BollardDirector$10K–Jan 21, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CABA short interest

High short interest. 17.8% of CABA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 68%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 38.37M CABA shares were sold short, 17.8% of the shares outstanding, down 2.3% from the report before. At the average daily volume of 4.68M shares, buying them all back would take about 8.2 trading days (days to cover).

Shares short, % of all shares

17.8%May 15Oct 3039.7%

Days to cover

8.2May 15Oct 3020.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202638.37M17.79%-2%4.68M8.2
Oct 15, 202639.29M23.17%+2%5.44M7.2
Sep 30, 202638.61M22.77%+16%6.13M6.3
Sep 15, 202633.33M19.66%-20%6.41M5.2
Aug 31, 202641.44M24.44%-3%4.96M8.3
Aug 14, 202642.80M25.24%+5%3.45M12.4
Jul 31, 202640.78M36.63%-1%2.21M18.4
Jul 15, 202641.01M36.84%+20%6.09M6.7
Jun 30, 202634.06M30.60%+30%7.86M4.3
Jun 15, 202626.24M23.57%+14%3.48M7.5
May 29, 202622.94M20.61%+0%3.02M7.6
May 15, 202622.84M20.52%+11%7.02M3.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cabaletta Bio company events

Cabaletta Bio filed 13 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Sep 14, 2026AnnouncementIn connection with Cabaletta Bio’s June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants that had an exercise price of $2.50 per whole share of its common stock and an expiration date of September 12, 2026. Filing
  4. Aug 13, 2026ResultsReleased financial results. Filing
  5. Jun 11, 2026VoteReported shareholder vote results. Filing
  6. Jun 3, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
  7. May 14, 2026ResultsReleased financial results. Filing
  8. May 14, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
  9. May 4, 2026AgreementCabaletta Bio, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., relating to an underwritten registered direct offering of 51,725,000 shares of the Company’s common stock, $0.00001 par value per share. Filing
  10. May 4, 2026AnnouncementCabaletta intends to present new clinical and translational data from 4 refractory patients that received rese-cel at the lowest dose without preconditioning in the RESET-PV ® (pemphigus vulgaris) trial at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held on May… Filing
  11. Apr 20, 2026AnnouncementCabaletta Bio, Inc. posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
  12. Mar 23, 2026ResultsReleased financial results. Filing
  13. Jan 12, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cabaletta Bio financials

Famous investors that hold CABA

5 of the 50 well-known investors we track reported holding CABA in their latest 13F filing. The largest position is Ken Griffin's, worth $5.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.71M$5.2M0.0%-23%
Israel Englander · Millennium ManagementQ3 2026640,361$1.2M0.0%-69%
Jim Simons · Renaissance TechnologiesQ3 2026272,700$524K0.0%-82%
Steve Cohen · Point72 Asset ManagementQ3 202678,671$151K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202625,719$49.4K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named CABA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Bain Capital Life Sciences Opportunities III, LP13G/A9.6%
Nov 16, 2026Cormorant Asset Management, LP13G/A2.6%
Nov 16, 2026Bain Capital Life Sciences Opportunities III, LP13G/A9.6%
Nov 16, 2026Cormorant Asset Management, LP13G/A2.6%
Nov 12, 2026Norges Bank13G/A4.0%
Nov 12, 2026Norges Bank13G/A4.0%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A8.0%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A13.1%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A8.0%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A13.1%
Oct 30, 2026Vanguard Capital Management13G/A3.8%
Oct 30, 2026Vanguard Capital Management13G/A3.8%
Oct 27, 2026BlackRock, Inc.13G/A7.7%
Oct 27, 2026BlackRock, Inc.13G/A7.7%

Questions about Cabaletta Bio, Inc. (CABA) stock

Who owns the most CABA stock?

The largest reported owner of Cabaletta Bio, Inc. (CABA) is Jennison Associates LLC, with 18.0% of the company. In total, 140 funds and institutions reported holding CABA at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CABA insiders buying or selling?

In the last 12 months, CABA insiders reported 8 open-market purchases worth $296K and no sales. The latest trade was on Jan 21, 2026. See every trade.

What is the short interest in CABA?

As of Oct 30, 2026, 38.37M CABA shares were sold short, 17.8% of the shares outstanding, down 2.3% from the report before. At the average daily volume of 4.68M shares, buying them all back would take about 8.2 trading days (days to cover). See the history.

Which famous investors hold CABA?

5 of the 50 well-known investors we track reported CABA in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $5.2M. See all holders.

Executive pay

Cabaletta Bio's chief executive was paid a total of $1.9M for the year ended Dec 31, 2025, down 76% from $8.1M the year before. In the last 12 months, Cabaletta Bio's executives and directors bought $296K of stock on the open market and sold none.

Chief executive, total pay$1.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$973KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.